Acute coronary syndromes (ACS) are a comprehensive disease concept characterized by
acute myocardial ischemia caused by disruption of coronary artery plaque and consequent …

For many years, bleeding has been perceived as an unavoidable consequence of strategies
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

In 2019, the Japanese Circulation Society published 2 guidelines in the field of coronary
artery disease (CAD):(1) a guideline for acute coronary syndrome (ACS) that integrated …

Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at
preventing the atherothrombotic complications in patients with a variety of coronary artery …

Background: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention with drug-eluting stents remains uncertain. We compared short-term (< …

Objectives The aim of this study was to compare short dual antiplatelet therapy (DAPT) and
de-escalation in a network meta-analysis using standard DAPT as common comparator …

The Japanese Circulation Society (JCS) published the “Guidelines for elective percutaneous
coronary intervention [PCI] in patients with stable coronary disease” in 2000. In 2006 …

Objective To evaluate the efficacy and safety of standard term (12 months) or long term (> 12
months) dual antiplatelet therapy (DAPT) versus short term (< 6 months) DAPT after …

Multiple guidelines and consensus papers have addressed the role of antithrombotic
strategies in patients with established coronary artery disease (CAD). Since evidence and …